The neuroendocrine tumors market is experiencing significant growth, fueled by advancements in cutting-edge technology. Innovations such as precision medicine, targeted therapies, and molecular diagnostics are revolutionizing treatment approaches. Breakthroughs in imaging techniques such as PET-CT scans and molecular imaging are enhancing early detection and accurate diagnosis. Furthermore, the emergence of immunotherapy and peptide receptor radionuclide therapy (PRRT) is expanding treatment options and improving patient outcomes. With a growing understanding of tumor biology and genetics, personalized medicine tailored to individual patients' needs is becoming increasingly feasible, promising a brighter future for neuroendocrine tumor management.
The Global Neuroendocrine Tumors Market size was valued at USD 3,232.02 million in 2023, is expected to reach 7,132.24 million by 2031, at a CAGR of 10.4% during the forecast period 2024 to 2031.
Below are the Top Five Neuroendocrine Tumors Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
F. Hoffmann-La Roche Ltd.
|
F. Hoffmann-La Roche Ltd. is a global pharmaceutical company with a significant presence in the neuroendocrine tumors (NETs) market. They focus on developing innovative therapies to address unmet medical needs in oncology, including NETs. Roche's flagship drug, Lanreotide, is a somatostatin analog used in the treatment of NETs. Additionally, the company invests in research and development to discover new treatment options and improve patient outcomes in this niche market.
|
|
America, Europe, Asia, Africa, Oceania
|
In August 2020, F. Hoffmann-La Roche Ltd announced that the European Commission had granted priority approval for marketing authorization for Rozlytrek for the treatment of adults and children aged 12 years suffering from advanced non-small cell lung cancer. The approval received is based on the cumulative analysis of phase II clinical trials, STARTRK-2. The approval received by the company would result in a rise in research collaborations, timely treatment of individuals, and a rise in revenue. It would exhibit a positive growth in the market.
|
|
2.
|
Bristol-Myers Squibb Company
|
Bristol-Myers Squibb Company has a portfolio that includes medications for neuroendocrine tumors (NETs). Their commitment to oncology research and development extends to NETs, aiming to provide effective treatment options for patients with these rare cancers. Bristol-Myers Squibb's expertise in immuno-oncology and targeted therapies positions them as key players in the NETs market.
|
|
North America, Europe, Asia-Pacific
|
In February 2021, Bristol-Myers Squibb Company declared that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had recommended approval of Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) for the first-line treatment of adults with advanced renal cell carcinoma (RCC). The positive approval received by the company would result in robust clinical trials, distribution of the drugs across the globe, and a rise in investments and research. It would deliver a positive growth in the market.
|
|
3.
|
Viatris Inc.
|
Viatris Inc. has a presence in the neuroendocrine tumors (NETs) market through its portfolio of oncology medications. With a focus on expanding access to affordable healthcare, Viatris aims to address the needs of patients with NETs by providing cost-effective treatment options. The company's dedication to innovation and collaboration underscores its commitment to improving outcomes for individuals affected by NETs.
|
|
Africa, Europe, America, and Asia-Pacific
|
In May 2020, Viatris Inc. Ireland made a financial donation to the Irish Cancer Society to help them reach patients who are afraid of seeking help during the pandemic. The team also made an emergency crisis donation to the country’s leading homeless and addiction charity. The initiative by the company would result in a rise in the emergent use of medical supplies. It would exhibit a positive growth in the market.
|
|
4.
|
Thermo Fisher Scientific Inc.
|
Thermo Fisher Scientific Inc. plays a crucial role in the neuroendocrine tumors (NETs) market by providing diagnostic solutions and technologies for the accurate detection and monitoring of these rare cancers. Their advanced molecular diagnostics and imaging tools enable healthcare professionals to diagnose NETs early and tailor treatment plans for better patient outcomes. Thermo Fisher Scientific's comprehensive approach to diagnostics supports the management of NETs across the continuum of care.
|
|
EMEA, APAC, America
|
In June 2018, Thermo Fisher Scientific Inc. launched the B·R·A·H·M·S KRYPTOR GOLD analyzer in Germany. The B·R·A·H·M·S KRYPTOR GOLD analyzer has been used for prenatal screening. This product is not FDA-cleared and not available for sale in the United States. The availability of this product is related to the registration status of the countries. The launch of the new product would result in the distribution of the product in hospitals and diagnostic centers to detect genetic defects and enhance the oncology product portfolio. It delivered a positive growth in the market.
|
|
5.
|
Novartis AG
|
Novartis AG is a leading pharmaceutical company with a strong presence in the neuroendocrine tumors (NETs) market. They offer a range of targeted therapies and treatment options for patients with NETs, including somatostatin analogs and molecularly targeted drugs. Novartis invests in research and development to advance the understanding of NETs and develop innovative therapies that improve patient outcomes. Their commitment to oncology innovation positions them as a key player in addressing the unmet needs of individuals with NETs.
|
|
Middle East and Africa, Europe, Asia-Pacific, America
|
In January 2018, Novartis AG proclaimed that Advanced Accelerator Applications, a subsidiary of Novartis AG, had received FDA approval for its new drug application Lutathera (lutetium Lu 177 dotatate), for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) including foregut, midgut and hindgut neuroendocrine tumors in adults. The FDA approval received by the company resulted in a rise in clinical trials and enhanced oncology product portfolio in neurology, and it would deliver a positive growth in the market.
|
Conclusion
The neuroendocrine tumors market is experiencing significant growth, fueled by advancements in cutting-edge technology. Innovations such as precision medicine, targeted therapies, and molecular diagnostics are revolutionizing treatment approaches. Breakthroughs in imaging techniques such as PET-CT scans and molecular imaging are enhancing early detection and accurate diagnosis. Furthermore, the emergence of immunotherapy and peptide receptor radionuclide therapy (PRRT) is expanding treatment options and improving patient outcomes. With a growing understanding of tumor biology and genetics, personalized medicine tailored to individual patients' needs is becoming increasingly feasible, promising a brighter future for neuroendocrine tumor management.
